GNFT

Genfit

Stock NASDAQ – Stock Market Prices, News & Analysis

Genfit est une société biopharmaceutique française spécialisée dans la recherche et le développement de thérapies pour les maladies métaboliques et inflammatoires, notamment la stéatohépatite non alcoolique (NASH).

$ 6.27
1.29 %

Genfit

$ 6.27
1.29 %
GNFT

Genfit est une société biopharmaceutique française spécialisée dans la recherche et le développement de thérapies pour les maladies métaboliques et inflammatoires, notamment la stéatohépatite non alcoolique (NASH).

Price history of Genfit
Price history of Genfit

Performance & Momentum

6 Months 63.49 %
1 Year 82.00 %
3 Years 52.55 %
5 Years 16.54 %

Strategic Analysis

Genfit • 2026

Genfit positions itself as a specialist player in the development of innovative therapies for metabolic and inflammatory diseases, with recognized expertise in NASH. Its model is based on targeted biotech innovation and diagnostic research to address unmet medical needs.

Strengths
  • Leadership in a high-potential niche therapeutic segment (NASH)
  • Strong scientific expertise combining therapeutics and diagnostics
  • Rapid growth driven by promising clinical prospects
Weaknesses
  • Dependence on clinical outcomes and regulatory approvals
  • High risk related to the biotechnology sector and intense competition
Momentum

Positive momentum reflects renewed investor confidence, supported by favorable performance trends over the past months and years. This dynamic suggests rising valuation linked to progress in clinical programs and growing interest in NASH.

Similar stocks to Genfit

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone